Table 2 Injection characteristics in study groups
Group 1 (42 eyes) | Group 2 (14 eyes) | |||||
|---|---|---|---|---|---|---|
Subgroup 1A | Subgroup 1B | Baseline to 1st switch | 1st switch to 2nd switch | After 2nd switch | ||
Type of treatment | Avastin | 6 (25%) | 3 (16.7%) |
| ||
Lucentis | 9 (37.5%) | 8 (44.4%) | ||||
Eylea | 9 (37.5%) | 7 (38.9%) | ||||
p = 0.86 | ||||||
Duration of treatment | 18 months | 42 eyes (100%) | 34.3 ± (16.1) | 50.8 ± (35) | 60.2 ± (31.4) | |
24 months | 32 eyes (76%) | |||||
Number of injections, mean (SD) | 11.8 ± (3.2) | 13.1 ± (3.1) | 4.9 ± (2) | 6.9 ± (4) | 3.8 ± (1) | |
Interval between injections, mean (SD) | 1.8 ± (0.2) | 1.7 ± (0.3) | 1.6 ± (0.3) | 1.7 ± (0.4) | 1.6 ± (0.3) | |
